Affinity Asset Advisors’s Kura Oncology KURA Stock Holding History

Affinity Asset Advisors’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-37,100	Closed	-$507K	–	71
2022 Q3	$507K	Buy	+37,100	New	+$572K	0.14%	59

Other funds holding KURA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Affinity Asset Advisors's KURA Position: Q4 2024 in Review

Affinity Asset Advisors sold out of Kura Oncology (KURA) in Q4 2024, closing a stake of 687,785 shares — an estimated $13.4M sold.

Affinity Asset Advisors first reported a position in KURA in Q4 2020 and held it in 16 quarters. The position peaked at $17M in Q2 2022. 185 funds tracked by Wall St. Rank hold KURA as of Q4 2024.

Affinity Asset Advisors reported no remaining Kura Oncology position as of Q4 2024 after selling out during the quarter.
Affinity Asset Advisors sold 687,785 Kura Oncology shares in Q4 2024, an estimated $13.4M.
Affinity Asset Advisors first reported a position in Kura Oncology in Q4 2020 and held it in 16 quarters.
Affinity Asset Advisors's Kura Oncology position peaked at $17M in Q2 2022.
185 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2024.

Based on Affinity Asset Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.